Table 3.
Treatment effects for all contrast in terms of patient global assessment (PGA VAS) along with 95% credible interval and probability that treatment is better than the comparator
| Intervention |
Comparator |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Placebo | MTX | aTNF | Tocilizumab | aTNF + MTX | Abatacept + MTX | Anakinra + MTX | Tocilizumab + MTX | ||
| Placebo |
Estimate |
0 |
14.32 |
17.35 |
27.69 |
33.49 |
27.98 |
23.04 |
29.43 |
| 95% CrI |
|
(-4.66, 32) |
(10.63, 25.39) |
(15.06, 40.53) |
(14.01, 51.89) |
(3.21, 50.46) |
(2.06, 42.8) |
(13.49, 44.66) |
|
| P(better) |
|
5% |
<1% |
<1% |
<1% |
2% |
2% |
<1% |
|
| MTX |
Estimate |
-14.32 |
0 |
2.91 |
13.22 |
19.05 |
13.62 |
8.72 |
15.06 |
| 95% CrI |
(-32, 4.66) |
|
(-12.59, 21.31) |
(0.76, 27.44) |
(14.36, 24.21) |
(-1.97, 28.4) |
(-0.37, 17.84) |
(5.66, 25.14) |
|
| P(better) |
95% |
|
34% |
2% |
<1% |
4% |
3% |
1% |
|
| aTNF |
Estimate |
-17.35 |
-2.91 |
0 |
10.29 |
16.09 |
10.60 |
5.83 |
12.00 |
| 95% CrI |
(-25.39, -10.63) |
(-21.31, 12.59) |
|
(-0.8, 20.37) |
(-2.65, 32.53) |
(-13.52, 31.58) |
(-15.01, 23.52) |
(-2.94, 24.98) |
|
| P(better) |
>99% |
66% |
|
3% |
4% |
16% |
23% |
4% |
|
| Tocilizumab |
Estimate |
-27.69 |
-13.22 |
-10.29 |
0 |
5.76 |
0.27 |
-4.46 |
1.71 |
| 95% CrI |
(-40.53, -15.06) |
(-27.44, -0.76) |
(-20.37, 0.80) |
|
(-8.91, 19.33) |
(-20.68, 19.62) |
(-21.41, 10.72) |
(-7.84, 10.29) |
|
| P(better) |
>99% |
98% |
97% |
|
17% |
49% |
77% |
30% |
|
| aTNF + MTX |
Estimate |
-33.49 |
-19.05 |
-16.09 |
-5.76 |
0 |
-5.40 |
-10.34 |
-4.00 |
| 95% CrI |
(-51.89, -14.01) |
(-24.21, -14.36) |
(-32.53, 2.65) |
(-19.33, 8.91) |
|
(-22, 10.07) |
(-20.94, -0.25) |
(-14.82, 6.97) |
|
| P(better) |
>99% |
>99% |
96% |
83% |
|
76% |
98% |
81% |
|
| Abatacept + MTX |
Estimate |
-27.98 |
-13.62 |
-10.60 |
-0.27 |
5.40 |
0 |
-4.86 |
1.39 |
| 95% CrI |
(-50.46, -3.21) |
(-28.4, 1.97) |
(-31.58, 13.52) |
(-19.62, 20.68) |
(-10.07, 22) |
|
(-22.16, 13.21) |
(-16.06, 20.05) |
|
| P(better) |
98% |
96% |
84% |
51% |
24% |
|
71% |
43% |
|
| Anakinra + MTX |
Estimate |
-23.04 |
-8.72 |
-5.83 |
4.46 |
10.34 |
4.86 |
0 |
6.30 |
| 95% CrI |
(-42.8, -2.06) |
(-17.84, 0.37) |
(-23.52, 15.01) |
(-10.72, 21.41) |
(0.25, 20.94) |
(-13.21, 22.16) |
|
(-6.65, 20.01) |
|
| P(better) |
98% |
97% |
77% |
23% |
2% |
29% |
|
12% |
|
| Tocilizumab + MTX | Estimate |
-29.43 |
-15.06 |
-12.00 |
-1.71 |
4.00 |
-1.39 |
-6.30 |
0 |
| 95% CrI |
(-44.66, -13.49) |
(-25.14, -5.66) |
(-24.98, 2.94) |
(-10.29, 7.84) |
(-6.97, 14.82) |
(-20.05, 16.06) |
(-20.01, 6.65) |
|
|
| P(better) | >99% | 99% | 96% | 70% | 19% | 57% | 88% | ||
P(better) = Probability that treatment (in row) is showing greater efficacy than comparator (in column); CrI = credible interval; aTNF = Anti-tumor necrosis factor.